Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease
{{output}}
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disease characterized by systemic inflammation. Although IL-6 receptor blockade with tocilizumab is an established treatment, Janus kinase (JAK) inhibition may offer broader immunom... ...
